Top Story

Trials begun to evaluate empagliflozin for treatment of HF

March 25, 2017

Two trials begun to study empagliflozin for the treatment of adults with HF with or without type 2 diabetes, according to a press release from Boehringer Ingelheim and Eli Lilly.

The outcome studies, part of the EMPEROR HF trial program, will investigate empagliflozin (Jardiance, Boehringer Ingelheim) in adults with HF with preserved ejection fraction or reduced ejection fraction.

In the Journals Plus

Stress fracture risk varies by race, sex

March 24, 2017
White U.S. Army soldiers were more likely to sustain a stress fracture over 10 years vs. soldiers of other races, with the highest risk observed among white women…
In the Journals

Increased insulin resistance found in patients with mild lupus

March 24, 2017
Patients with mild lupus had increased insulin resistance and hyperglucagonemia, while having normal glucose tolerance and a preserved beta-cell function and skeletal…

GOP, Trump pull AHCA due to lack of support

March 24, 2017
Reportedly acting on orders from President Donald J. Trump, House Republican leaders today again postponed a vote that would have overhauled the nation’s health…
In the Journals Plus

Resveratrol, placebo comparable for pain management in endometriosis

March 24, 2017
In women with endometriosis, resveratrol was no more effective than placebo for reducing pain associated with the disease when each was added to a monophasic…
More News Headlines »

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Meeting News

VIDEO: Expert identifies new ways to improve profitability

March 2, 2017
More »



Diabetic Retinopathy: Preferred Practice Patterns in Screening and Management

This activity is supported by an educational grant from Regeneron.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Current Issues
View the Current Issues